Synthesis of cefazolin under sequential continuous-flow conditions

The sequential continuous-flow synthesis method addresses the challenges of producing cefazolin by enabling efficient, safe, and flexible production of cefazolin, overcoming the limitations of traditional methods with its controlled flow system and reduced exposure to toxic compounds.

WO2024262578A1PCT designated stage expired Publication Date: 2024-12-26THE UNIV OF TOKYO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/022415
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-23
Filing Date
2024-06-20
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

The existing methods for manufacturing antibiotics like cefazolin are costly, space-intensive, and pose safety risks due to the need for dedicated facilities and equipment, making it difficult to produce these highly sensitizing compounds efficiently and safely, especially in local settings where demand fluctuates.

Method used

A sequential continuous-flow synthesis method is developed, which involves reacting 7-aminocephalosporanic acid with 2-mercapto-5-methyl-1,3,4-thiazole and then with 1H-tetrazol-1-ylacetyl halide in a controlled flow system, allowing for efficient production of cefazolin without the need for intermediate isolation and minimizing exposure to toxic compounds.

Benefits of technology

This method enables a lower-cost, space-saving, and highly safe synthesis of cefazolin, allowing for flexible production quantities and reducing the risk of cross-contamination, thereby addressing the challenges of producing essential antibiotics locally.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-C000001
    Figure JPOXMLDOC01-APPB-C000001
  • Figure JPOXMLDOC01-APPB-C000002
    Figure JPOXMLDOC01-APPB-C000002
  • Figure JPOXMLDOC01-APPB-C000003
    Figure JPOXMLDOC01-APPB-C000003
Patent Text Reader

Abstract

The present disclosure relates to a sequential continuous-flow synthesis of cefazolin, which is a vital first-choice drug used for the prevention of primary infection in most surgeries, was investigated. Rapid flow and efficient mixing of substrates in suitable flow reactors enabled the target compound to be obtained in a short period without any intermediate isolation. A flexible system design that can be applied from a small-scale to medium-scale synthesis could be demonstrated, and optimal parameters were established to realize the synthesis. A 0.3 mol / h scale synthesis was achieved in 54% isolated yield with 13.75 g / h dL space-time-yield of cefazolin. The obtained material had an acceptable impurity profile and could be purified by simple acid-base extraction and precipitation.
Need to check novelty before this filing date? Find Prior Art

Description

SYNTHESIS OF CEFAZOLIN UNDER SEQUENTIAL CONTINUOUS-FLOW CONDITIONSThe invention relates to the field of pharmaceutical antibiotic drug, and in particular relates to a continuous-flow synthesis of cefazolin.Cefazolin sodium is one of the β-lactam antibiotics belonging to the first-generation cephalosporines, more broadly cephems. It is known to be active against both Gram-positive and Gram-negative bacteria and has a broad antibacterial spectrum.1In addition, cefazolin sodium is a vital first-choice drug that is used for the prevention of primary infection in most surgeries.2Because of its importance, cefazolin sodium is registered as one of the essential medicines defined by the WHO.3Cefazolin is mainly produced by chemical derivatization of 7-amino cephalosporanic acid (7-ACA, 5), which is derived by chemoenzymatic hydrolysis of Cephalosporine C isolated from a fungus of the genus Acremonium; however, its synthesis using enzymes has also been extensively studied.4,5Although it was commercialized in 1971, cefazolin is still widely studied because of its importance. In addition, the demand for antibiotics, including cefazolin, is growing and the use of this drug is increasing worldwide.6Accordingly, there is increasing urgency to manufacture this type of important drug in locations close to medical practices.7Moreover, because the demand for these products fluctuates greatly, it is important to have flexible control over the amount that is manufactured locally to meet the demands of local communities. However, the essence and details of manufacturing methods have been converted into know-how. Thus, barriers for new entrants to manufacture remain and cannot be ignored as this is an issue that stands in the way of social demand for a stable supply of important drugs. Therefore, the development of efficient manufacturing methods is crucial not only for supplying sufficient amounts of drugs to meet global demand, but also for maintaining a stable supply of essential drugs at the local level.When manufacturing highly sensitizing biologically active compounds such as antibiotics, it is necessary to isolate manufacturing sites and equipment to prevent contamination and to ensure safety, and air-filtering equipment should be strictly controlled.8Therefore, when starting to manufacture new antibiotics, it is necessary to prepare a dedicated area for manufacture, which requires a large initial capital outlay to cover costs such as the site and construction of a dedicated section, as well as the cost of isolated equipment. Consequently, in addition to the above general issues, there are many safety and financial issues that need to be resolved, making it difficult to introduce or reconstruct production of highly sensitizing antibiotics. Therefore, a major challenge for research on manufacturing these families of drug molecules is to break away from conventional manufacturing methods and develop lower-cost, space-saving, highly safe, traceable, and reliable methods.Continuous-flow synthesis of organic molecules has great advantages in manufacturing high value-added compounds compared with conventional batch synthetic methods, including space saving of experimental equipment, improvement of energy efficiency, and enhanced safety.9There are several key elements that are particularly important advantages of continuous-flow synthetic organic chemistry over conventional batch methods. The first is control of rapid and ultrarapid reactions by controlling reaction time as reaction space.10Another important aspect is the ease of safety management, which comes from the use of a small and closed reaction space such as tubing and columns.11Furthermore, it is possible to integrate a plurality of reaction steps in one operation while meeting the demand of minimizing external exposure due to instability, high toxicity, and short lifetime. In the production of highly active antibiotics, it is possible to benefit greatly from the latter two characteristic features. In particular, sequential continuous-flow synthesis, in which multiple reactions are connected together, can reduce contact between highly sensitizing compounds and workers and limit cross-contamination with other compounds, for example, by isolating only one compartment when the antibiotic synthesis is implemented. Furthermore, the ability to arbitrarily control the amount of production is attractive to manufacturers. In addition to reducing both cost and safety risks, such next-generation systems can be used to produce only the required amount of compound at the required time without having to hold unstable intermediate inventories of drugs, which will be essential for realizing a sustainable and resilient society. Here, to leverage the advantages of a sequential continuous-flow synthesis in which two or more multistep reactions are connected, purification of intermediate compounds should be avoided. To this end, it is important not only to connect reactions, but also to verify the interdependencies before and after ligation. This is because carry-over including unreacted starting products and by-products from an upstream reaction can adversely affect a reaction in subsequent stages. Moreover, to deliver the final product in pure form efficiently, it is also important to make efforts to minimize the carry-over from upstream reaction stages.There has been still a need to develop a lower-cost, space-saving, highly safe, and highly stable as well as traceable method for manufacturing highly sensitizing antibiotics.In order to achieve the foregoing objects, the present inventors conducted intensive studies to find that a sequential continuous-flow approach allowed lower-cost, space-saving, highly safe, and highly stable as well as traceable synthesis of the highly sensitizing antibiotics, in particular, cefazolin.That is, the present invention provides the following.[1] A continuous-flow synthetic method of a compound represented by formula 2:or a pharmaceutically acceptable salt, comprising steps:(i) in the presence of a base and water, reacting 7-aminocephalosporanic acid (Compound 5)with a solution of 2-mercapto-5-methyl-1,3,4-thiazole (Compound 6)to form Intermediate 3, and(ii) reacting the intermediate with 1H-tetrazol-1-ylacetyl halide (Compound 4)(X is halogen).[2] The continuous-flow synthetic method according to [1], wherein the step (i) is carried out while flowing the base, water, Compound 5 and Compound 6 to a first reactor.[3] The continuous-flow synthetic method according to [1], wherein the step (ii) is carried out while flowing a reaction mixture in the step (i) from the first reactor to a second reactor connected to the first reactor, and while feeding a solution of Compound 4 to the second reactor.[4] The continuous-flow synthetic method according to [1] or [2], wherein an amount of Compound 5 to be fed to the first reactor per unit volume per unit hour, is controlled so that F5 / VR1is from 0.01 to 1.00 (mmol / min・mL), andwherein F5is a molar flow rate of Compound 5; and VR1is an internal volume of a first reactor (R1).[5] The continuous-flow synthetic method according to [4], wherein the F5 / VR1is from 0.02 to 0.60 (mmol / min・mL).[6] The continuous-flow synthetic method according to any one of [1] to [5], wherein Compound 6 is further fed to a separate reactor connected to the first reactor.[7] The continuous-flow synthetic method according to any one of [1] to [6], wherein the base is at least one selected from the group consisting of Na3PO4, Na2HPO4,K3PO4, K2HPO4, K3PO4, triethylamine and a combination thereof.[8]The continuous-flow synthetic method according to a wherein an organic base is added to the reaction of step (i).[9] The continuous-flow synthetic method according to [8], wherein the organic base is at least one selected from the group consisting of 2,6-lutidine, 3,4-lutidine, 2,4-lutidine, pyridine, 4-dimethylaminopyridine, N,N-dimethylaniline, tetrabutylammonium bromide, imidazole, 1,2-dimethylimidazole, 1-methylimidazole, 2,3,5,6-tetramethylpyrazine, 1,4-diazabicyclo[2.2.2]octane (DABCO), 3-methyl-1-octylimidazolium chloride, 1-ethyl-3-methylimidazolium chloride, and a combination thereof.

[0010] The continuous-flow synthetic method according to any one of [1] to [9], wherein the solution of Compound 4 is comprised of Compound 4 dissolved in an aprotic polar solvent.

[0011] The continuous-flow synthetic method according to

[0010] , wherein the aprotic polar solvent is selected from the group consisting of acetonitrile, acetone, tetrahydrofuran and dichloromethane.

[0012] The continuous-flow synthetic method according to any one of [1] to

[0011] , wherein the step (i) is carried out at a range of from 60℃ to 90℃.

[0013] The continuous-flow synthetic method according to any one of [1] to

[0012] , wherein the step (ii) is carries out at a range of from 10℃ to room temperature.

[0014] The continuous-flow synthetic method according to any one of [1] to

[0013] , wherein the pharmaceutically acceptable salt of the compound is a sodium salt.By a sequential continuous-flow approach, we succeeded in a lower-cost, space-saving, highly safe, and highly stable as well as traceable synthesis of cefazolin.The accompanying drawings, which are incorporated herein and constitute part of this specification, are illustrative of particular embodiments of the present disclosure and do not limit the scope of the present disclosure. The drawings are not to scale and are intended for use in conjunction with the explanations in the following detailed description.FIG. 1 shows a synthetic route of cefazolin from 7-ACA (5). The reaction of 7-ACA (hereinafter, “7-ACA” is also referred to as “Compound 5”) with Compound 6 to yield Intermediate 3 corresponds to step (i), and the reaction of Intermediate 3 with Compound 4 corresponds to step (ii).FIG. 2 shows a screening on bases for the thioesterification. “Base A” refers to a base used along with Compound 5, and “Base B” refers to a base used along with Compound 6.FIG. 3 shows a two-step sequential continuous-flow synthesis of Cefazolin 2.FIG. 4 shows a two-step sequential continuous-flow synthesis of Intermediate 3. Concs. a, b and c are concentration of Compound 6, K3PO4,and K2HPO4, respectively.FIG. 5 shows a revised flow setup and potential side products. “Additive” can be interchangeably used with “an organic base.”FIG. 6 shows a scale-up of flow synthesis of Cefazolin 2 and derivatization of Cefazolin sodium 1.FIG. 7 shows a synthetic route of cefazolin.FIG. 8 shows an investigation on base for thioesterification between 7-ACA (5) and MMTD (6). An equivalent of Base 2 denoted as “x eq.” is 1.15 or 2.3. These correspond to Table 7.FIG. 9 shows a flow reaction for the synthesis of Intermediate 3 using single pump.FIG. 10 shows an examination of the sequential continuous-flow reaction for the synthesis of Cefazolin 2.FIG. 11 shows an optimization of the modified reaction of thioetherification. Amounts x, y and z are shown in Table 4.FIG. 12 shows an examination of the modified sequential continuous-flow reaction for the synthesis of Cefazolin 2. An amount 4-Cl, the conc. of y, and the follow rate are, respectively, listed in Table 5, as “Stoichiometry [eq.]”, “Conc. [M]”, and “v3[mL / min].”FIG. 13 shows a purification of Cefazolin 2 and crystallization of Cefazolin sodium 1.FIG. 14 shows a large-scale sequential continuous-flow reaction for the synthesis of Cefazolin 2.FIG. 15 shows an illustration of large scale of sequential continuous-flow equipment.FIG. 16 shows photos of large-scale synthesis modules: (a) large-scale water bath; (b) stainless loop reactors (TR 1aL, TR 1bLand TR 2L); (c) In-line flow meter and pressure sensor; (d) Thermocouple port through tube connector; (e) T-shape tube connector.FIG. 17 shows an investigation on additive for the sequential continuous-flow reaction.FIG. 18 shows a batch investigation for suitable solvent system of amidation step. “Base” and “Solvent” are listed in Table 16.FIG. 19 shows a control experiment of one-pot two-step synthesis of Cefazolin 2 under batch conditions.The following discussion omits or only briefly describes conventional features of the disclosed technology that are apparent to those skilled in the art. Reference to various embodiments does not limit the scope of the claims attached hereto. Additionally, any examples set forth in this specification are intended to be non-limiting and merely set forth some of the many possible embodiments for the appended claims. Further, particular features described herein can be used in combination with other described features in each of the various possible combinations and permutations. A person of ordinary skill in the art would know how to use the instant invention, in combination with routine experiments, to achieve other outcomes not specifically disclosed in the examples or the embodiments.Unless otherwise specifically defined herein, all terms are to be given their broadest possible interpretation including meanings implied from the specification as well as meanings understood by those skilled in the art and / or as defined in dictionaries, treatises, etc. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art in the field of the disclosed technology. It must also be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless otherwise specified, and that the terms "includes" and / or "including," when used in this specification, specify the presence of stated features, elements, and / or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and / or groups thereof. Additionally, methods, equipment, and materials similar or equivalent to those described herein can also be used in the practice or testing of the disclosed technology.A flow synthesis is a synthesis method in which raw materials and reactants are pumped through a flow path system consisting of a tube several millimeters in diameter and a reactor (a flow reactor) with grooves carved into the metal, and continuous reaction, extraction and purification operations are performed. Herein, “a continuous-flow” is also referred to as “a sequential continuous-flow.” In particular, a sequential continuous-flow system refers to a flow reaction system, in which a single continuous-flow reaction is connected in series and two or more transformations are performed as a sequential continuous-flow reaction. In this method, since chemical reactions are carried out in small quantities in the flow path, there is little risk of runaway reactions or explosions. In addition, since the reaction is carried out in a connected flow path, contamination of impurities can be prevented. Further, the transition to industrial mass production can be made seamlessly by layering the equipment based on conditions studied at the laboratory level.The present continuous-flow synthesis (hereinafter referred to as “flow synthesis”) comprises two steps, i.e., step (i) and step (ii).Step (i) of the present synthetic method is directed to reacting Compound 5 with Compound 6, respectively in the presence of bases, in a first reactor (R1), to yield Intermediate 3.Step (ii) of the present synthetic method is directed to reacting Intermediate 3 obtained in step (i) with a solution of Compound 4-X (X is halogen) in a second reactor (R2) connected to R1, to yield Compound 2. Halogen is selected from the group consisting of Cl, F, Br and I.A reactor includes, for example, microreactors or tube reactors made of SUS (Stainless Used Steel), Hastelloy, resin, glass, etc.The first reactor and second reactor used herein may be a tube reactor (TR). If a third reactor, a fourth reactor, or the like, are further used in a continuous-flow method, these reactors may also be a tube reactor. Herein, “R1” can be interchangeably used with “TR1.” “R2” can be interchangeably used with “TR2.”Examples of a base includes, but not limited to, at least one selected from the group consisting of Na3PO4, Na2HPO4,K3PO4, K2HPO4, triethylamine, and a combination thereof. In particular, phosphate buffering conditions are beneficial to avoid undesirable decomposition of the starting material, Compound 5. An organic base such as triethylamine is also preferable, however, inorganic bases may be preferred due to ease of postreaction work-up.Hereinafter, a base used along with Compound 5 refers to “Base A,” and a base used along with Compound 6 refers to “Base B” (see for example, Table 1, FIG.2). In the combination of Base A and Base B, these bases may be the same or different each other. The ratio of Base A and Base B is, for example, from 1:9 to 9:1, preferably from 1:5 to 5:1, more preferably from 1:3 to 3:1. Base A and Base B may be respectively used in an amount of 0.1 to 2.0 eq. relative to Compound 5 or Compound 6.Compound 5, Compound 6, Base A and Base B are combined, for example, by the ratio of from 1:1:1:1 to 1:1:1:9.Compound 6 may be further fed to a separate reactor connected to the R1 in order to consume Compound 5 completely. Additional amount of Compound 6 may be from 0.1 to 1.0 eq. relative to Compound 6 which was already provided in step (i).Optionally, an organic base may be added to the reaction of step (i) in order to accelerate the following amidation reaction for preventing side reactions and improvement of the yield. The organic base may be used in an amount of 0.1 to 1.0 eq. relative to Compound 5 or Compound 6. An amount of the organic base to be used relative to Compound 5 or Compound 6 is, for example, 0.01 to 0.1 eq., preferably 0.01 to 0.05 eq.The organic base used herein includes, but not limited to, at least one selected from the group consisting of 2,6-lutidine, 3,4-lutidine, 2,4-lutidine, pyridine, pyridine N-oxide, 4-dimethylaminopyridine (DMAP), N,N-dimethylaniline, tetrabutylammonium bromide (TBABr), triethylamine, N,N-dimethylaniline, imidazole, 1,2-dimethylimidazole, 1-methylimidazole, 2,3,5,6-tetramethylpyrazine, 1,4-diazabicyclo[2.2.2]octane (DABCO), 3-methyl-1-octylimidazolium chloride, 1-ethyl-3-methylimidazolium chloride, and a combination thereof.Compound 4-X may be used by from 1.0 to 5.0 eq., preferably 2.0 to 3.0 eq. relative to Compound 5. In a case where the amount of 4-Cl is increased, the desired reaction with Intermediate 3 is increased, thereby suppressing the formation of undesired side products.A solvent used to prepare a solution of Compound 4-X includes, for example, an aprotic polar solvent selected from the group consisting of acetonitrile, acetone, tetrahydrofuran, dichloromethane, water, and a combination thereof. Among these, water / acetonitrile is preferable. The ratio thereof is preferably from 1:2 to 1:8, more preferably from 1:2 to 1:5, and particularly preferable 1: 4.5 (see Table 2).The above ratio is of critical importance, since a rapid mixing and an amount of a cosolvent to water are expected to affect the amidation strongly.In the continuous-flow synthetic method, an important index, F / V, a molar flow per reactor volume, should be fixed in addition to a substance composition, irrespective of the concentration, flow rate of the mother solution, or reactor size. Therefore, F5 / VR1(which is also referred to as F5 / VTR1) index should also remain constant, and an amount of Compound 5 to be fed to the first reactor (R1) per unit volume per unit hour, is preferably controlled so that F5 / VR1index is from 0.01 to 1.00 (mmol / min・mL) [wherein F5is a molar flow rate of Compound 5; and VR1is an internal volume of a first reactor (R1)]. More preferably, F5 / VR1index is from 0.01 to 0.90, more preferably from 0.01 to 0.80, more preferably from 0.01 to 0.7, more preferably from 0.02 to 0.7, particularly preferably from 0.02 to 0.60 (Table 5). If F5 / VR1index is less than 0.01, the system will not be able to produce the product in a sufficient amount, while if F5 / VR1index is greater than 1.00, the system will not be able to give a sufficient yield. In both cases, sufficient productivity will not be provided.Also, once the F5 / VR1index is determined, suitable feed conditions of 4-Cl are automatically fixed.Examples of a pharmaceutically acceptable salt of the compound represented by formula I incudes, but not limited to, salts with inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid and the like; salts with organic acid such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, phthalic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, para-toluenesulfonic acid and the like; salt with amino acid such as lysine, arginine, ornithine, glutaminic acid, aspartic acid and the like; salts with alkali metal such as sodium, potassium, lithium and the like; salts with alkaline earth metal such as calcium, magnesium and the like; salts with metal such as aluminum, zinc, iron and the like; salts with organic base such as methylamine, ethylamine, diethylamine, trimethylamine, triethylamine, ethylenediamine, piperidine, piperazine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N-methylglucamine, N,N'-dibenzylethylenediamine and the like; ammonium salt and the like. Among these salts, salts with alkali metal such as sodium, potassium or lithium are preferable, and a sodium salt is more preferable.We have achieved a continuous-flow synthesis of cefazolin, and even a 30-fold scaling-up of the synthesis (FIG.6). This was enabled by the characteristics of flow reactions, well-controlled rapid reactions through efficient mixing, and a sequential system that does not require any intermediate isolation. A flexible system design that enables small-, medium-, and large-scale reaction has been demonstrated, and optimal parameters to operate the system have been established. In addition, although performed manually in this work, acceptable purification was achieved by simple acid-base extraction and precipitation. The current process, from supplying raw materials to obtaining cefazolin in the crude state, could be achieved in a closed system without external exposure, which has the potential to be developed into a safer system with minimal risk of cross-contamination or human exposure. With these achievements, it is expected that the local production of essential medicines in the required amount, on demand, will be realized in the near future. Such systems are crucial in modern societies.After the completion of the synthetic reaction, the usual work-up treatment of the reaction mixture, involving washing with a suitable solvent (for example, ethyl acetate), acidification, and extraction with a suitable solvent (for example, ethyl acetate), a solid material that corresponds to Compound 2. According to the1H NMR analysis, the solid material showed a 13.75 g / h dL STY (Space-time-yield) and showed reasonable agreement with that of the small-scale investigation (see Table 5, entry 4). For the solid material obtained for purification, an usual work-up as described above, extraction, and acidification give a purified Compound 2. Further purification accompanied by, for example, a sodium salt conversion gives the desired cefazolin sodium 1.The disclosed technology is next described by means of the following examples. The use of these and other examples anywhere in the specification is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified form. Likewise, the invention is not limited to any particular preferred embodiments described herein. Indeed, modifications and variations of the invention may be apparent to those skilled in the art upon reading this specification, and can be made without departing from its spirit and scope. The invention is therefore to be limited only by the terms of the claims, along with the full scope of equivalents to which the claims are entitled.1H-Tetrazol-1-Ylacetyl Chloride (4-Cl) SolutionTo a three-neck round-bottom flask, equipped with a magnetic stirrer, were added 1H-tetrazol-1-ylacetic acid (4) (1 eq.) and THF as a solvent under Ar atmosphere, and the solution was then cooled to 0 ℃ and stirred. To the stirred solution was added a catalytic amount of N,N-dimethylformamide by using a syringe, followed by the dropwise addition of oxalyl chloride (1.5 eq.) by syringe. The reaction mixture was stirred for 1 h at 0 ℃, then warmed to room temperature and stirred for 2 h. Upon completion of the reaction, the solvent was removed under vacuum to give 1H-tetrazol-1-ylacetyl chloride (4-Cl). The prepared reagent was used without purification. The acid chloride was dissolved in MeCN (0.0125-0.1 mol / L) to give 4-Cl solution, which was used for the sequential continuous-flow reaction.Sequential continuous-flow Synthesis of Cefazolin (FIG. 5 and Table 5)The acid chloride 4-Cl prepared as shown above was dissolved in acetonitrile at the required concentration (0.0333-0.0667 mol / L) to give 4-Cl solution, which was used for the sequential continuous-flow reaction. A tube reactor (TR 2; PTFE tube, 2.0 mm i.d. × 1.0 m L) system was prepared and the reactor was submerged in a water bath. The whole system was then rinsed with acetonitrile by using Pump 3. A flow setup consisting of TR 1a and TR 1b was constructed.For the mother solution supplied from Pump 1, an aqueous solution of 7-ACA (5) (0.2 mol / L, 1.0 eq.), K3PO4(0.2 mol / L, 1.0 eq.), 2-mercapto-5-methyl-1,3,4- thiadiazole (6) (0.2 mol / L, 1.0 eq.), K2HPO4(0.8 mol / L, 4.0 eq.), and 2,6-lutidine (0.01 mol / L, 0.05 eq.) was prepared. An aqueous solution of 6 supplied from Pump 2, consisting of 2-mercapto-5-methyl-1,3,4-thiadiazole (6) (0.2 mol / L, 0.5 eq.), K3PO4(0.1 mol / L, 0.25 eq.), and K2HPO4(0.4 mol / L, 1.0 eq.) was also prepared.The two-step system was then put into operation and allowed to stabilize for 30 min. The feeding solution of Pump 3 was then replaced with the 4-Cl solution, and the stream was combined with the outlet solution of the two-step TR 1 system at a micromixer. The flow rate of 4-Cl solution was controlled appropriately to adjust the stoichiometry to 2-3 eq. relative to 5. After stabilization of the whole flow system for 30 min, the outlet solution was collected for 30 min. The resulting solution was then washed with AcOEt and acidified with 10 % HCl aq. to ca. pH 2.0 (checked with test paper). The acidified solution was extracted with AcOEt and H2O, and the organic phase was dried with Na2SO4, filtered, and the solvent was removed under vacuum to give the crude product. The yield of cefazolin 2 was calculated by1H-NMR (internal standard: 1,1,2,2-tetrachloroethane) in DMSO-d6. The crude product was isolated by flash column chromatography (CH2Cl2 / MeOH = 10:1 - 5:1 + 1% AcOH) to give the corresponding product 2 in the given yield.Results:A canonical synthetic strategy for attaining cefazolin (2) from readily available commercial compounds is a two-step,4, 5three-component coupling consisting of thiadiazole thioetherification of the cephalosporane core with 6 and successive amidation with activated tetrazole-1-acetic acid derivative (4) (FIG. 1). Therefore, we started our continuous-flow investigation with the base-promoted substitution reaction of 7-ACA (5) with 2-mercapto-5-methyl-1,3,4-thiadiazole (MMTD, 6) in aqueous media. Our initial flow setup consisted of two plunger pumps, Pump 1 and Pump 2, for feeding 5 and 6, respectively. Both starting materials were dissolved in water by addition of 1.0 eq. of base. The two streams were merged with a T-shape mixer and transferred into a 1.0 mm × 10 m (7.85 mL) PTFE tube reactor, TR 1, warmed to 80 ℃ in a water bath. For the initial investigation to screen suitable bases, both substrates were flowed at 0.15 mL / min, and thus the residence time could be estimated to be 26.2 min (Table 1).Therefore, we provided a 30-min conditioning period to stabilize the flow reaction, followed by a 30-min sampling period for determination of the yield of the product. The total flow rate was 0.3 mL / min, and the system could reliably collect around 9.0 mL of the solution without being affected by pressure loss.Based on an accumulated knowledge of cefazolin production, phosphate buffering conditions were anticipated to be beneficial to avoid undesirable decomposition of the starting material, 7-ACA 5, and the results shown in Table 1 would also indicate such an effect. A 70% yield and 8.0 mmol / h dL space-time-yield were obtained when sodium or potassium phosphate / hydrogen phosphate systems were adopted. The use of organic base also gave the same yield; however, inorganic bases may be preferred due to ease of postreaction work-up. Although the yield of the intermediate 3 was not satisfactory and further improvement of the yield may be possible by using other additives such as Lewis acids or by using an excess of the nucleophile or the electrophile, it was important that no unwanted reagents would be carried over to the next step. Not only would this make purification of the final product difficult, but it can also induce side reactions with the activated tetrazole-1-acetic acid derivative 4, further complicating the product mixture. The yields achieved in this study were also comparable with that of a known cefazolin synthesis.12For these reasons, we decided to accept this result and proceeded to the next amidation step.The output of the previous two-pump setup was diverted to the amidation step, but a 7.85 mL tube reactor TR 1 was inserted between Pump 1 and a T-shape mixer, and another 2.0 mm × 1 m (3.14 mL) tube reactor TR 2 was connected at the outlet of the mixer. A mother solution consisting of a mixture of 7-ACA (5, 0.05 M), MMTD (6, 0.05 M), K3PO4(0.05 M), and K2HPO4(0.20 M) in H2O was flowed at 0.3 mL / min by using Pump 1 and an acetonitrile solution of as-prepared tetrazole-1-acetyl chloride (TAACl, 4-Cl) was provided from Pump 2 at the desired flow rate.We first compared the results of the sequential continuous-flow amidation with different numbers of equivalents of acid chloride (as-prepared from the corresponding acid with oxalyl chloride using a small amount of DMF), and found no significant difference between the use of 4 and 2 eq.; thus, the use of 2 eq. of the acid chloride was selected as the standard conditions (Table 2, entries 1 and 2). By fixing the number of equivalents of 5 / 6 and acid chloride 4-Cl to 1:2, and then varying the concentration and flow rate of the chloride, the effect of the water / acetonitrile ratio of the final mixed solution was investigated. This parameter is of critical importance, as rapid mixing and the amount of a cosolvent to water were expected to affect the amidation strongly. The two-step yield from 5 was improved to around 60% when a more dilute 0.0125 M acetonitrile solution of 4-Cl was supplied at a faster flow rate of 2.4 mL / min (Table 2, entries 2-4). The total flow rate of the mixed solution to TR 2 was 2.7 mL / min and the residence time was estimated to be 70 sec; rapid mixing at the T-mixer might be advantageous for the reaction. The result encouraged us to examine the use of a faster feed of the mother solution to enhance productivity (Table 2, entries 5-9), and it was found that providing the mother solution at 0.8 mL / min also gave a satisfactory 65% yield with 12.89 g / h dL STY (entry 8). Shorter residence time for TR 1, estimated to be 9.8 min, was also beneficial for the outcome. We also tested the use of a doubly concentrated mother solution of 5, because faster 0.9 mL / min feed of the mother solution resulted in a drop in the yield. This attempt was also successful by maintaining the other parameters, the STY value could be improved to around 25-26 g / h dL; the addition of 2,6-lutidiine slightly improved the yield and reproducibility for consistent production of the target 2 in around 65% yield (entry 11). Although an actual role of 2,6-lutidine was unclear, we assumed that it activated 4-CL and enhanced amidation. Moreover, considering similar effects of tetrabutylammonium bromide and tetramethylammonium bromide shown in SI, these additives might function as phase-transfer catalysts. We also tried to reduce the amount of acetonitrile solvent used in the generation of acid chloride 4-Cl, and found that the use of a concentrated solution of 4-Cl with slower flow rate at 3.6 mL / min gave the same yield and STY with reduced solvent consumption (entry 12). According to the results shown in entry 12, the final composition of the solution for amidation was H2O / acetonitrile = 1:4.5, indicating that the residence time of around 26-43 sec was a major factor for satisfactory reactivity in the second amidation step, rather than the H2O / acetonitrile ratio. It was considered that this two-step synthesis was substantially superior to the conventional batch method in terms of efficiency. Although not optimized, when we attempted to synthesize cefazolin (2) by one-pot, two-step reactions in a batch mode, the yield of the desired product was only 4%.The one-pot, two-step reaction consisted of two successive reactions, 7-ACA (5) with MMTD (6, 1.0 eq) in the presence of 2.15 eq of K3PO4, and direct amidation with 2 eq of 4-Cl. The crude1H NMR spectrum after usual work-up indicated production of 2 in 4% yield. Additionally, the reaction of isolated 3 with 4-Cl in the presence of K3PO4under Schotten-Baumann-like conditions resulted in the formation of 2 in 56% yield. This would be related to mixing efficiency. In the batch reaction, when the solution of 4-Cl was added to the basic aqueous solution including 3, 4-Cl reacted with water resulting in decomposition.From the results obtained in the investigations up to this stage, basic parameters and conditions for further investigations were extracted and are summarized in Table 3. Here, an important index, F / V, molar flow per reactor volume, should be fixed in addition to a substance composition; for example, regarding the thioetherification reaction, irrespective of the concentration, flow rate of the mother solution, or reactor size, the F5 / VTR 1index obtained as a function of these parameters should remain constant. We indicate other parameters such as residence time (tR), reactor volume (VTR 1), flow rate (v1), and concentration of 5 (C5), in Table 3, as interdependence values. Also, once first reaction conditions were determined, suitable feed conditions of 4-Cl were automatically fixed. According to the results for the amidation step, the F3 / VTR 2index of 0.051 mmol / min mL would be beneficial for keeping acceptable reactivity.Before moving to scale up the synthesis of cefazolin (2) and final purification to access cefazolin sodium (1), we examined the formation of a side product (side product A in Table 6). According to the HPLC chromatogram of the crude solution in the latter part of Table 2, we noted that a nonnegligible amount of a side product, probably bearing a carboxylic acid moiety in the structure, was formed in the second step (Table 6). This side product clearly made it difficult to isolate the target product by acid-base extraction. In addition, reproducibility of the yield of the target product under the above conditions was somewhat problematic; therefore, a further refinement of reaction conditions was required at this stage. Based on the chromatogram of the outlet solution of TR 1 under particular conditions showing the presence of a significant amount of unreacted 7-ACA (5), we noted that the first process was incomplete, giving a clue that the side product might be an amidation product between unreacted 5 with 4-Cl. To suppress this side-product formation, we examined the two-step addition of MMTD (6) in the first thioetherification step (Table 4).Fixing the composition of materials in the additional 6 solution to 6 / K3PO4 / K2HPO4= 1:0.5:2, equivalency of additional 6 to 5 in the mother solution was investigated, and all resulted in a little improvement in the yield of 3 compared with those in Table 1 (Table 4). Addition of 0.5 eq. of 6 at a newly inserted 7.85 mL tube reactor TR 1b gave the intermediate in 76% yield (Table 4, entry 1), and the mother solution including 2,6-lutidine also provided the same level of improvement (entry 4). Although insertion of TR 1b sacrificed STY, this change did not affect productivity per unit period, and we decided to prioritize improving impurity profiles. Application of this new system to the sequential continuous-flow was carried out as illustrated in FIG. 5. However, an initial trial was disappointingly unsuccessful and resulted in the production of a small amount of 2 (Table 5, entry 1). We therefore decided to shorten the residence time in TR 2 as the acetonitrile / water mixture ratio increased based on our previous experience. These trials increased the yield of 2 to 50% (entry 3). We confirmed that production of the problematic side product presumably occurred from the reaction between 5 and 4-Cl and could be suppressed by utilizing the new system; however, under these conditions, the appearance of another side reaction product became apparent (side product B in Table 6). Careful examination of this new side reaction alerted us to the presence of an unexpected N-acetylation of the intermediate 3 through the reaction between 3 and the residue of acetate anion from thioetherification. We envisioned that this problem might be overcome by rate acceleration on the amidation step and found that several additives other than 2,6-lutidine possessed the ability. However, we ultimately decided to use 3.0 eq. of the acid chloride 4-Cl for this step, instead of 2.0 eq. (entry 4). The yield of 2 obtained under the revised reaction system reached 60% with 13.90 g / h dL STY with relatively clean crude HPLC chromatogram (Table 6). We assumed that increasing the amount of 4-Cl promoted the desired reaction with 3 and consequently suppressed the formation of undesired side products.With these refined conditions in hand, we finally examined a 30-fold scaling-up of the synthesis of cefazolin (2) with a two-step sequential continuous-flow system, as illustrated in FIG. 6. Fixing material stoichiometry of the mother solution as shown in Table 3 and keeping the key substrate concentration to 0.2 M, the mother solution was flowed at 25 mL / min flow rate. The mother solution also contained 0.05 eq. of 2,6-lutidine. To maintain F / V1index with around 0.0204 mmol / min mL, TR 1aLwith 211.95 mL reactor volume (i.d. 3.0 mm × 30 m) was used. The estimated F / V1index was 0.0235 mmol / min mL, which would be a negligible difference considering the residence time. Additional 0.5 eq. of 6 with base was supplied through another pump with the same concentration and at half of the flow rate. The combined solution with 37.5 mL / min flow rate was gathered with 4-Cl flow at a micromixer. To keep the 4-Cl / 5 ratio to 3.0 and the H2O / acetonitrile ratio to 1:8, the 0.05 M solution of 4-Cl was provided at 300 mL / min flow rate; thus, the total stream was 337.5 mL / min. For TR 2L, we used a 141.3 mL tube to keep the F / V3index less than 0.31 mol / h dL. We installed flow meters on the outlet side of Pump 1Land Pump 3L, and pressure sensors at five points on the whole flow line to monitor the flow rate, which confirmed that there were no problems on the flow lines during the operation. In addition, nine thermocouples were inserted in the system (FIG. 6) to prepare for sudden clogging; however, such abnormalities did not occur during operation. We performed the two-step reaction for more than 10 min, excluding a preconditioning period. First, we collected the outlet solution for 1 min to conduct an analysis, and then collected it for another 10 min to undertake an isolation operation. After the usual work-up treatment of the former sample, involving washing with ethyl acetate, acidification, and extraction with ethyl acetate, we could obtain a solid material (cru2) that corresponded to 56% yield of 2. The1H NMR analysis with an internal standard indicated the solid material was cefazolin (2), corresponding to 57% yield based on the theoretical concentration. Indeed, we could isolate 2 in 54% yield from the recovered NMR sample, and thus the yields based on weight of solid material and crude1H NMR data were consistent. This result indicated a 13.75 g / h dL STY and showed reasonable agreement with that of the former small-scale investigation (Table 5, entry 4). For the sample obtained for purification, we first conducted the usual work-up as described above, and then extracted into an aqueous phase by using a sodium hydrogen carbonate solution. Acidification with aq. HCl gave a precipitate, which corresponded to 7.2 g of purified 2 (pur2). Based on the amount of crude solid materialcru2, the purification yield was 59%. Further purification accompanied by a sodium salt conversion gave the desired cefazolin sodium (1) in 59% yield from the formerpur2. The final cefazolin sodium 1 possessed sufficient purity of around 98%.Example 1: General experimental details1H-NMR and13C-NMR spectra were recorded on JEOL ECX-600 spectrometer in DMSO-d6 (2.50 ppm and 39.5 ppm) and D2O (4.79 ppm). High Performance Liquid Chromatography analysis was recorded on SHIMADZU SPD-20AV. GL Science ODS column 10 mm, 4.0 x 150 mm was used for HPLC analysis. 7-ACA was purchased from Tokyo Chemical Industry Co., Ltd., BLDpharm Inc., and Combi-blocks Inc.. 2-Mercapto-5-methyl-1,3,4-thiadiazole was purchased from Tokyo Chemical Industry Co., Ltd. and Combi-blocks Inc.. 1H-tetrazole-1-acetic acid was purchased from Zhejiang Hailan Chemical Group Co., Ltd.. K3PO4, K2HPO4, Na3PO4, Na2HPO4, Et3N, N,N-dimethylformamide and MeCN were purchased from FUJIFILM Wako Pure Chemical Co. Ltd.. 2,6-Lutidine was purchased from Aldrich. Tetrahydrofuran was purchased from Kanto Chemical Co., Inc.. Oxalyl chloride was purchased from Tokyo Chemical Industry Co., Ltd.As for the sequential continuous-flow reaction system, Intelligent Pump UI-22-110 (plunger pump) of FLOM Inc. or Q-5-6R-UP-S (diaphragm pump) of TACMINA CORPORATION were used for small scale investigation. Unless otherwise noted, two types of pumps with different drive systems were used without distinction. Q-100-6T-P-S (diaphragm pump) of TACMINA CORPORATION, XPL-1-STSX-XWX (diaphragm pump) of TACMINA CORPORATION and XPL-1-XTCX-XWX (diaphragm pump) of TACMINA CORPORATION were used for scale-up synthesis. Constant temperature bath TBN402 of ADVANTEC TOYO KAISHA, Ltd. was used for a heating substance. Clamp-on flow sensor FD-XS1 of KEYENCE CORPORATION was used for a flow sensor and FD-XA1 of KEYENCE CORPORATION was used for a flow sensor controller. Pressure sensor SVS-1 / 4-1MS of Surpass Industry Co., Ltd. was used for a pressure sensor. Thermocouple ST-1 of AMNIS CORPORATION was used for temperature measurement. Midi logger GL840-M of GRAPHTEC Corporation was used for confirmation and recording of the sequential continuous-flow reaction data.Example 2: Flow synthesis of intermediate 3 from 7-ACA 5 and MMTD 6A PTFE loop (tube reactor, TR 1, 1.0 mm i.d. x 10 m L) was warmed to 80 ℃ in a water bath. One of the ends of the tube was placed into a receiver flask, and the other side was mounted with a T-shape connector. Two pumps, Pump 1 and Pump 2, were filled with H2O and the tubing ends from the pumps were attached to the T-shape connector to build the flow system. From the two pumps H2O was flowed through the reaction loop at 0.15 mL / min each to rinse the entire system. Then the feeding solutions for Pump 1 and Pump 2 were replaced from H2O to solutions containing [ 7-ACA (5) (0.1 mol / L, 1.0 eq.) and Base 1 (1.0 eq.) in H2O, for Pump 1] and [ 2-mercapto-5-methyl-1,3,4-thiadiazole (6) (0.1 mol / L, 1.0 eq.) and Base 2 (1.15 of 2.23 eq.) in H2O, for Pump 2], respectively, and each flowed at 0.15 mL / min. The system was stabilized for 30 minutes, and then the outlet solution was collected for 30 minutes. The collected solution was washed with AcOEt and then acidified with HCl aq. To ca. pH 2.0 checked by pH test paper. A generating solid was collected by vacuum filtration and washed with H2O then acetone. The residue was dried under vacuum to give the corresponding product 3 to 47 - 70% yield (shown in Table 7).Example 3: Flow synthesis of intermediate 3 from 7-ACA using single pumpTR 1 (a PTFE tube loop, 1.0 mm i.d. x 10 m L) was warmed to 80 ℃ in a water bath. One of the ends of the tube was placed into a receiver flask, and the other side was connected to the outlet of Pump 1 through one-way connector. From the pumps H2O was flowed through the reaction loop at 0.3 mL / min to rinse the entire system. Then the feeding solution for the pump was replaced to a solution of 7-ACA (5) (0.05 mol / L, 1.0 eq.), K3PO4(1.0 eq.), 5-methyl-1,3,4-thiadiazole-2-thiol (6) (0.05 mol / L, 1.0 eq.) and K2HPO4(2.23 or 4.0 eq.) in H2O and was flowed at 0.3 mL / min to the reactor. The system was stabilized for 30 minutes, and then the outlet solution was collected for 30 minutes. The collected solution was washed with AcOEt and then acidified with HCl aq. to ca. pH 2.0 checked by pH test paper. A generating solid was collected by vacuum filtration and washed with H2O then acetone. The residue was dried under vacuum to give the corresponding product 3 to 70 - 71% yield (shown in Table 8).Example 4: Sequential continuous-flow synthesis of CefazolinPreparation of 1H-tetrazol-1-ylacetyl chloride (4-Cl) solutionA three-neck round bottom flask was equipped with magnetic stirrer and added 1H-tetrazol-1-ylacetic acid (4) (1 eq.) and THF as a solvent under Ar atmosphere, then cooled at 0 ℃ and stirred. To the stirred solution was added catalyzed amount of N,N-dimethylformamide via syringe. To the mixture was then added dropwise oxalyl chloride (1.5 eq.) via syringe. The reaction mixture was stirred for 1 h under 0 ℃, then warmed up to room temperature and stirred for 2 h. After the reaction, the solvent was removed under vacuum to give 1H-tetrazol-1-ylacetyl chloride (4-Cl). The prepared reagent was used without purification. The acid chloride was dissolved in MeCN (0.0125-0.1 mol / L) to give 4-Cl solution which was used for next sequential continuous-flow reaction.Sequential continuous-flow reaction using the original flow systemTR 1 (a PTFE tube loop, 1.0 mm i.d. x 10 m L) was warmed to 80 ℃ in a water bath. One of the ends of the tube was placed into a receiver flask, and the other side was connected to the outlet of Pump 1 through one-way connector. From the pump H2O was flowed through the reaction loop at 0.3 mL / min to rinse the TR 1 system.Meanwhile, a PTFE loop (tube reactor, TR 2, 2.0 mm i.d. x 1.0 m L) was submerged to a water bath, and one of the tube ends was placed into another receiver flask. The other end was connected to an outlet port of a T-shaped micromixer, α-600 type of Nakamura Choukou Co. Ltd. To one of the inlet ports of the micromixer was connected an outlet tube from Pump 2 charged with acetonitrile, and the other inlet port was capped by a plug. This TR 2 system was then rinsed with acetonitrile.A substrate solution consisted of 7-ACA (5) (required concentration), K3PO4(1.0 eq. to5), 5-methyl-1,3,4-thiadiazole-2-thiol (6) (1.0 eq. to 5), K2HPO4(4.0 eq. to 5) and 2,6-lutidine (0.05 eq. to 5), if necessary, in H2O was prepared and was started to flow at required flow rate into TR 1. After the supply of this mother solution maintained for 30 minutes, the supply of the mother solution was stopped for a short period, and its tube end was connected to the unplugged inlet port of the micromixer in TR 2 system. At the same time of re-starting supply of the mother solution, 4-Cl in acetonitrile (required concentration) was started to flow form Pump 2 at required flow rate. The sequential continuous-flow system was stabilized for another 30 minutes, and then the outlet solution form TR 2 was collected for 30 minutes. The reaction solution was washed with AcOEt, acidified with 10% HCl aq. and then extracted with AcOEt and H2O. The organic phase was dried with Na2SO4, filtered and removed a solvent under vacuum. The yield of the product 2 was calculated by1H-NMR (internal standard: 1,1,2,2-tetrachloroethane) in DMSO-d6 to 44 - 65% yield (shown in Table 2).Example 5: Modification for the flow synthesis of intermediate 3The previous TR 1 (a PTFE tube loop, 1.0 mm i.d. x 10 m L) was used as TR 1a, and the mother solution and the reactor system were prepared in the same manner as Example 4.Meanwhile, another PTFE loop (tube reactor, TR 1b, 1.0 mm i.d. x 10 m L) was prepared, and one of the tube ends was placed into a receiver flask. The other side was connected to a T-shaped mixer.To one of ports of the mixer was connected an outlet tube from Pump 2 charged with H2O, and the other port was capped by a plug. TR 1b system was then rinsed with H2O. A substrate solution consisted of 7-ACA (5) (0.2 M), K3PO4(0.2 M), 5-methyl-1,3,4-thiadiazole-2-thiol (6) (0.2 M), K2HPO4(0.8 M) and 2,6-lutidine, if necessary, in H2O was prepared and was flowed at 0.8 mL / min of flow rate to TR 1a. After the supply of this mother solution maintained for 30 minutes, the supply of the mother solution was stopped for a short period, and its tube end was connected to the unplugged inlet port of the T-shape connector in TR 1b system. At the same time of re-starting supply of the mother solution, an additional 6 (required amount) aqueous solution including required amounts of K3PO4and K2HPO4was started to flow form Pump 2 at 0.4 mL / min of flow rate. The sequential continuous-flow system was stabilized for another 30 minutes, and then the outlet solution form TR 2 was collected for 30 minutes. The collected solution was washed with AcOEt and acidified with HCl aq. to ca. pH 2.0 checked by pH test paper. A generating solid was collected by vacuum filtration and washed with H2O then acetone. The residue was dried under vacuum to give the corresponding product 3 to 69 - 76% yield (shown in Table 4).Example 6: Modification for the sequential continuous-flow synthesis of cefazolinPreparation of the acid chloride 4-Cl was shown in Example 4. The acid chloride was dissolved in acetonitrile at required concentration (0.0333 - 0.0667 mol / L) to give 4-Cl solution which was used for sequential continuous-flow reaction. A TR 2 (PTFE tube, 2.0 mm i.d. x 1.0 m L) system was prepared as the same manner shown in Example 4. The reactor was submerged to a water bath, and the whole system was rinsed with acetonitrile by using Pump 3. A flow setup for revised two-step preparation of the intermediate 3 which consists of TR 1a and TR 1b was constructed as shown in Example 5.For the mother solution which will be provided from Pump 1, aqueous solution of 7-ACA (5) (0.2 mol / L, 1.0 eq.), K3PO4(0.2 mol / L, 1.0 eq.), 2-mercapto-5-methyl-1,3,4-thiadiazole (6) (0.2 mol / L, 1.0 eq.), K2HPO4(0.8 mol / L, 4.0 eq.), and 2,6-lutidine (0.01 mol / L, 0.05 eq.) was prepared. For aqueous solution of additional 6 supply which will be provided form Pump 2, 2-mercapto-5-methyl-1,3,4-thiadiazole (6) (0.2 mol / L, 0.5 eq.), K3PO4(0.1 mol / L, 0.25 eq.) and K2HPO4(0.4 mol / L, 1.0 eq.) was prepared.The two-step system was then put into operation as shown in Example 5 and was stabilized for 30 minutes. The feeding solution of Pump 3 was then replaced with the 4-Cl solution, and the stream was combined with the outlet solution of the two-step TR 1 system at a micromixer. The flow rate of 4-Cl solution was controlled appropriately to adjust the stoichiometry to 2 - 3 eq. for 5. After stabilization of the whole flow system for 30 minutes, the outlet solution was collected for 30 minutes. The resulting solution was then washed with AcOEt and acidified with 10 % HCl aq. to ca. pH 2.0 checked by pH test paper. The acidified solution was extracted with AcOEt and H2O, and organic phase was dried Na2SO4, filtered, and remove the solvent under vacuum to give the crude product. The yield of cefazolin 2 was calculated by1H-NMR (internal standard: 1,1,2,2-tetrachloroethane) in DMSO-d6 to trace - 60% yield. The crude product was isolated by flash column chromatography (CH2Cl2 / MeOH = 10 / 1 - 5 / 1 + 1% AcOH) to give the corresponding product 2 to 57% yield (shown in Table 5).Example 7: Conversion from Cefazolin to Cefazolin sodiumTo the solution of sequential continuous-flow synthesized reactant was back extracted with AcOEt and H2O. The separated water phase was acidified with 10% HCl aq. and extracted with AcOEt and H2O. Then the organic phase was back extracted with NaHCO3aqueous solution. The water phase was acidified with 80% AcOH aq. to ca. pH 5.0 checked by pH test paper. The acidified water phase was added charcoal (1.0 w / w% calculated for NMR yield shown in the continuous-flow synthesis of cefazolin) and alumina (2.0 w / w% calculated for same method of charcoal addition), then warmed up to 40 ℃, stirred for 15 min, and filtered off charcoal and alumina. The filtrate was further acidified with 10% HCl aq. to ca. pH 1.0 checked by pH test paper. The generating solid was collected with vacuum filtration and washed with small amount of acetone. The residue was dried under vacuum to give cefazolin (2) to 60% yield from flow reaction.To the cefazolin (2) which from above method was added NaHCO3(1 eq.) and H2O (1 M). Then to the cefazolin aqueous solution was added four times volume of 2-propanol. The solution was allowed to stand in a cold dark place. The obtained solid was collected with vacuum filtration and washed with 2-propanol, then dried under vacuum to give cefazolin sodium (1) to 88% yield.Example 8: The final sequential continuous-flow reaction for Cefazolin synthesis in large scalePreparation of the acid chloride 4-Cl was shown in Example 4. The acid chloride was dissolved in acetonitrile at 0.05 mol / L of concentration to give 4-Cl solution which was used for sequential continuous-flow reaction.For the mother solution which will be provided from Pump 1L, aqueous solution of 7-ACA (5) (0.2 mol / L, 1.0 eq.), K3PO4(0.2 mol / L, 1.0 eq.), 2-mercapto-5-methyl-1,3,4-thiadiazole (6) (0.2 mol / L, 1.0 eq.), K2HPO4(0.8 mol / L, 4.0 eq.), and 2,6-lutidine (0.01 mol / L, 0.05 eq.) was prepared. For aqueous solution of additional 6 supply which will be provided form Pump 2L, 2-mercapto-5-methyl-1,3,4-thiadiazole (6) (0.2 mol / L, 0.5 eq.), K3PO4(0.1 mol / L, 0.25 eq.) and K2HPO4(0.4 mol / L, 1.0 eq.) was prepared.TR 2L(stainless tube, 3.0 mm i.d. x 10 m L) system was newly prepared as the similar manner shown in Example 6. Several specific notes are listed below. Positions of equipment were illustrated in S9 or FIG. 6.# TACMINA XPL-1-XTCX-XWX was used for Pump 3L.# Two thermocouples were equipped through T-shape connector inside TR 3L(FIG. 19(d)).# Two other thermocouples were equipped through T-shape connector to the outside of TR 3L.# Two pressure sensors were installed in the line between the micromixer and TR 2L, and between Pump 3Land the micromixer.# Flow rate of the stream from Pump 3L was monitored through in-line flowmeter.# The measuring instruments were connected to the data logger.TR 1Lsystem consisted of two 3.0 mm i.d. x 30 m L stainless tube loops were prepared. One stainless tube loop was designated as TR 1aL, and one end was connected to Pump 1L. The other end was connected to the other loop designated as TR 1bLvia a T-shape connector. Another port of the T connector connected with Pump 2L. The entire TR 1Lsystem was placed in a water bath and heated to 80 ℃. The end of TR 1bLwas connected to the micromixer of TR 2 system. Several specific notes are listed below. Positions of equipment were illustrated in S9 or FIG. 6.# TACMINA XPL-1-STSX-XWX was used for Pump 1L.# TACMINA Q-100-6T-P-S was used for Pump 2L.# Two thermocouples were equipped through T-shape connector inside TR 1aLand TR 1bL, respectively.# One other thermocouple was equipped through T-shape connector between Pump 1Land TR 1L.# Two pressure sensors were installed in the line between Pump 1Land TR 1L, and TR 1bLand the micromixer.# Flow rate of the stream from Pump 1Lwas monitored through in-line flowmeter.# The measuring instruments were connected to the data logger.The TR 1Lsystem for synthesis of the intermediate 3 was started and stabilized for 20 minutes and the outlet during the stabilization process was ejected from the system. The feeding of 4-Cl solution by Pump 3Lwas then activated at 300 mL / min. The entire sequential continuous-flow system was stabilized for 5 minutes. Then the outlet flow solution was fractionated for 1 minute (for confirmation of1H-NMR yield and isolated yield) and another fraction of 10 minutes flow (used for precipitation step) was collected separately. The collected reaction solution for 1 minute was then washed with AcOEt and acidified with 10 % HCl aq. to ca. pH 2.0 checked by pH test paper. The acidified solution was extracted with AcOEt and H2O, and organic phase was dried Na2SO4, filtered, and remove the solvent under vacuum to give the crude product. The yield of cefazolin (2) was calculated by1H-NMR (internal standard: 1,1,2,2-tetrachloroethane) in DMSO-d6 to 57% yield. The crude product was isolated by flash column chromatography (CH2Cl2 / MeOH = 10 / 1 - 5 / 1 + 1% AcOH) to give the corresponding product 2 to 54% yield (1.22 g).To the Cefazolin (2) which from above method was added NaHCO3(1 eq.) and dissolved in H2O (1 mol / L). The resulting solution was added four times volume of 2-propanol. The solution was allowed to stand in a cold dark place. The generated precipitate was collected with vacuum filtration and washed with 2-propanol. The residue was dried under vacuum to give Cefazolin sodium (1) to 59% yield from Cefazolin precipitation. The Cefazolin sodium (1) was then analyzed with HPLC (mobile phase; phosphate buffer (Na2HPO4: NaH2PO4= 1 : 19) 800 mL / MeOH 200 mL, the sample dissolved in 0.1 mol / L phosphate buffer pH 7.0) to 97.952% purity.Example 9: Reaction data for the large amount of sequential continuous-flow conditionThe reaction data for the large amount of sequential continuous-flow condition are shown in FIG. 15.Example 10: Examination data for the effect of additivesExample 11: HPLC analysis for the reaction solution of the sequential continuous-flow reactionHPLC analysis for the reaction solution of entry 3 of Table 5 is as follows.Example 12: HPLC analysis for Cefazolin (2) and a sodium salt thereofThe results of HPLC analysis for Cefazolin (2) and Cefazolin sodium (1) are as follows.Example 13: Batch investigation for suitable solvent system of amidation stepBefore performing the amidation reaction in flow system, we conducted a rough study of the reaction solvent system. Since the thioetherification is carried out in a basic aqueous solution, we focused on water-miscible solvent systems, and found that acetonitrile is the most suitable co-solvent, although the basic conditions are different shown in Table 16. THF could not completely dissolve the acid chloride. An organic solvent system such as DCM was also investigated; however, the intermediate 3 was not soluble even in its acid form, and the desired product yield was about 30%.Comparative Example 1: Control experiment of one-pot two-step synthesis of Cefazolin (2) under batch conditionsSince the current sequential continuous-flow reaction is essentially a one-pot process, a one-pot batch Cefazolin synthesis was performed for comparison. We have not optimized this process.As standard conditions, thioetherification was performed in an aqueous solution under potassium phosphate base conditions, a base was further added to the solution, and an acetonitrile solution of acid chloride 4-Cl was added dropwise to perform amidation reaction. However, such an approach resulted in formation of only 4% the corresponding amides being identified by crude1H-NMR.Example 14: Characterization data for product and intermediateNMR peaks for (6R, 7R)-7-amino-3-(5-methyl-1,3,4-thiadiazol-2-ylthiomethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (intermediate 3)1H NMR (600 MHz, D2O + NaHCO3) d (ppm): 4.85 and 4.59 (2H, ABq, J = 5.0 Hz, CH2), 4.34 and 3.78 (2H, ABq, J = 13.7 Hz, CH2), 3.64 and 3.26 (2H, ABq, J = 17.9 Hz, CH2), 2.58 (3H, s). (FIG. 30).13C NMR (150 MHz, D2O + NaHCO3) d (ppm): 170.9, 170.2, 168.9, 167.0, 131.8, 118.4, 62.8, 59.1, 39.0, 27.1, 15.5. (FIG. 31).References for peak identification: Numata, M.; Minamida, I.; Yamaoka, M.; Shiraishi, M.; Miyawaki, T. Japan Patent 1976, JPS5111782.NMR peaks for Cefazolin sodium (1)1H NMR (600 MHz, DMSO-d6) d (ppm): 9.53 (1H, d, J = 8.5 Hz, NH), 9.38 (1H, s, tetrazole CH), 5.54 (1H, dd, J = 4.8, 8.5 Hz, CH), 5.40 and 5.35 (2H, ABq, J = 16.5 Hz, CH2), 4.98 (1H, d, J = 4.8, CH), 4.51 and 4.35 (2H, ABq, J = 12.4 Hz, CH2) 3.61 and 3.39 (2H, ABq, J = 17.2 Hz, CH2), 2.65 (3H, s, CH3). (FIG. 32).13C NMR (150 MHz, DMSO-d6) d (ppm): 166.0, 165.7, 165.5, 164.2, 162.7, 154.2, 133.8, 115.4, 58.5, 57.0, 49.2, 37.0, 26.6, 15.3. (FIG. 33).References for peak identification: Sivakumar, B.; Parthasarathy, K.; Murugan, R.; Jeyasudha, R.; Murugan, S.; Saranghdar, R. J. Sci. Pharm., 2013, 81, 933Theforegoing merely illustrates the principles of the disclosure. Any examples setforth in this specification are not intended to be limiting and merely setforth some of the many possible embodiments for the appended claims. Thoseskilled in the art will readily recognize various modifications and changesthat may be made without following the example embodiments and applicationsillustrated and described herein, and without departing from the true spiritand scope of the following claims.All references cited and / or discussed in this specificatin are incorporated herein by reference in their entireties and to the same extent as if each reference was individually incorporated by reference.REFERENCES1. T. Nishino, Y. Yokota, T. Tanino, Jpn. J. Chemother. 1980, 28 S-1, 58-82.2. D. L. Bratzler, E. P. Dellinger, K. M. Olsen, K.T. M. Perl, P. G. Auwaerter, K. M. Bolon, D. N. Fish, L. M. Napolitano, R. G. Sawyer, D. Slain, J. P. Steinberg, R. A. Weinstein, Am. J. Health-Syst. Pharm. 2013, 70, 195-283.3. WHO Model List of Essential Medicines - 22ndList, 2021, who.int / publications / i / item / WHO-MHP-HPS-EML-2021.024. (a) A. Palomo-Coll, A. L. Palomo-Coll, C. P. Nicolau, Tetrahedron 1985, 41, 5133-5138. (b) R. Fernandez-Lafuente, J. M. Guisan, M. Pregnolato, M. Terreni, Tetrahedron Lett. 1997, 38, 4693-4696. (c) I. Estruch, A. R. Tagliani, J. M. Guisan, R. Fernandez-Lafuente, A. R. Alcantara, L. Toma, M. Terreni, Enzyme Microb. Technol. 2008, 42, 121-129. (d) M. Qiu, CN101696215B. (e) X. Wang, B. Wang, W. Yu, X. Yang, Y. Wenig, CN102617607B. (f) Z. Wu, W. Yu, X. Yang, S. Tao, CN 1102321101B. (g) G. Yang, W. Xin, T. Fei, H. Chuanshan, W. Yongjin, L. Fengxia, S. Hongbin, D. Fumin, F. Meiju, CN 104910188A. (h) F. Miaoquing, Z. Yeqing, S. Bin, X. Lei, Z. Xuwei, M. Quingshuang, Z. Baishui, W. Lei, CN 105541870B. (i) F. Miaoquing, W. Fengzhe, M. Bin, Z. Baishui, Y. Yuping, M. Quingshuang, CN 110396103B.5. (a) M. Kostadinov, A. Nikolov, N. Tsoneva, N. Petkov, Appl. Biochem. Biotechnol. 1992, 33, 177-182. (b) O. H. Justiz, R. Fernandez-Lafuente, J. M. Guisan, P. Negri, M. Pregnolato, M. Terreni, J. Org. Chem. 1997, 62, 9099-9106. (c) J. I. Won, C. G. Kim, J. H. Kim, J. H. Lee, Y. J. Jeon, Appl. Biochem. Biotechnol. 1998, 69, 1-9. (d) P. Bonomi, T. Bavaro, I. Serra, A. Tagliani, M. Terreni, D. Ubiali, Molecules 2013, 18, 14349-14365. (e) L. Wang, A. V. Sklyarenko, D. Li, A. I. Sidorenko, C. Zhao, J. Li, S. V. Yarotsky, Bioprocess Biosyst. Eng. 2018, 41, 1851-1867. (f) A. V. Sklyarenko, I. A. Groshkova, A. I. Sidorenko, S. V. Yarotsky, Appl. Biochem. Microbiol. 2020, 56, 452-464.6. E. Y. Klein, T. P. Van Boeckel, E. M. Martinez, S. Pant, S. Gandra, S. A. Levin, H. Goossens, R. Laxminarayan, Proc. Nat. Acc. Sci. 2018, 115, E3463.7. In 2019, the supply of cefazolin sodium in Japan was temporarily suspended due to quality problems with the API imported from overseas: H. Honda, S. Murakami, Y. Tokuda, Y. Tagashira, A. Takamatsu, Clin. Infect. Dis. 2020, 71, 1783-1789.8. (a) U. S. Food and Drug Administration, Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination, 2022, https: / / www.fda.gov / regulatory-information / search-fda-guidance-documents / non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination-0. (b) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7, 2000.9. (a) X. Y. Mak, P. Laurino, P. H. Seeberger, Beilstein J. Org. Chem. 2009, 5 No. 19. (b) D. Webb, T. F. Jamison, Chem. Sci. 2010, 1, 675-680. (c) J. Wenger, S. Ceylan, A. Kirchning, Chem. Commun. 2011, 47, 4583-4592. (d) J. Wenger, S. Ceylan, A. Kirchning, Adv. Synth. Catal. 2012, 354, 17-57. (e) I. R. Baxendale, J. Chem. Technol. Biotechnol., 2013, 88, 519-552. (f) T. Tsubogo, T. Ishikawa, S. Kobayashi, Angew. Chem. Int. Ed., 2013, 52, 6590-6604. (g) J. Pastre, D. L. Browne, S. V. Ley, Chem. Soc. Rev. 2013, 42, 8849-8869. (h) W.-J. Yoo, H. Ishitani, Y. Saito, B. Laroche, S. Kobayashi, J. Org. Chem. 2020, 85, 5132-5145.10. (a) J. Yoshida, Flash Chemistry - Fast Organic Synthesis in Micro Systems, WILEY-VCH, Weinheim, 2008. (2) J. Yoshida, A. Nagaki, T. Yamada, Chem. Eur. J., 2008, 14, 7450-7459. (c) J. Yoshida, Chem. Rec., 2010, 10, 332-341. (d) J. Yoshida, Y. Takahashi, A. Nagaki, Chem. Commun., 2013, 49, 9896-9904.11. (a) C. J. Mallia, I. R. Baxendale, Org. Process Res. Dev. 2016, 20, 327-360. (b) M. Movsisyan, E. I. P. Delbeke, J. K. E. T. Berton, C. Battilocchio, S. V. Ley, C. V. Stevens, Chem. Soc. Rev. 2016, 45, 4892-5136. (c) N. Kockmann, P. Thenee, C. Fleischer-Trebes, G. Laudadio, T. Noel, React. Chem. Eng. 2017, 2, 258-280.12. K. Kariyone, H. Harada, M. Kurita, T. Takano, J. Antibiot. 1970, 23, 131-136.The continuous-flow synthesis method may allow a closed system without external exposure, which has the potential to be developed into a safer system with minimal risk of cross-contamination or human exposure.

Claims

1. A continuous-flow synthetic method of a compound represented by formula 2: or a pharmaceutically acceptable salt, comprising steps: (i) in the presence of a base and water, reacting 7-aminocephalosporanic acid (Compound 5) with a solution of 2-mercapto-5-methyl-1,3,4-thiazole (Compound 6) to form Intermediate 3, and (ii) reacting the intermediate with 1H-tetrazol-1-ylacetyl halide (Compound 4) (X is halogen).

2. The continuous-flow synthetic method according to claim 1, wherein the step (i) is carried out while flowing the base, water, Compound 5 and Compound 6 to a first reactor.

3. The continuous-flow synthetic method according to claim 1, wherein the step (ii) is carried out while flowing a reaction mixture in the step (i) from the first reactor to a second reactor connected to the first reactor, and while feeding a solution of Compound 4 to the second reactor.

4. The continuous-flow synthetic method according to claim 1, wherein an amount of Compound 5 to be fed to the first reactor per unit volume per unit hour, is controlled so that F5 / VR1is from 0.01 to 1.00 (mmol / min・mL), and wherein F5is a molar flow rate of Compound 5; and VR1is an internal volume of a first reactor (R1).

5. The continuous-flow synthetic method according to claim 1, wherein the F5 / VR1is from 0.02 to 0.60 (mmol / min・mL).

6. The continuous-flow synthetic method according to any one of claims 2 to 5, wherein Compound 6 is further fed to a separate reactor connected to the first reactor.

7. The continuous-flow synthetic method according to claim 1, wherein the base is at least one selected from the group consisting of Na3PO4, Na2HPO4,K3PO4, K2HPO4, K3PO4, triethylamine and a combination thereof.8.The continuous-flow synthetic method according to claim 1, wherein an organic base is added to the reaction of step (i).

9. The continuous-flow synthetic method according to claim 8, wherein the organic base is at least one selected from the group consisting of 2,6-lutidine, 3,4-lutidine, 2,4-lutidine, pyridine, 4-dimethylaminopyridine, N,N-dimethylaniline, tetrabutylammonium bromide, imidazole, 1,2-dimethylimidazole, 1-methylimidazole, 2,3,5,6-tetramethylpyrazine, 1,4-diazabicyclo[2.2.2]octane (DABCO), 3-methyl-1-octylimidazolium chloride, 1-ethyl-3-methylimidazolium chloride, and a combination thereof.

10. The continuous-flow synthetic method according to claim 1, wherein the solution of Compound 4 is comprised of Compound 4 dissolved in an aprotic polar solvent.

11. The continuous-flow synthetic method according to claim 10, wherein the aprotic polar solvent is selected from the group consisting of acetonitrile, acetone, tetrahydrofuran and dichloromethane.

12. The continuous-flow synthetic method according to claim 1, wherein the step (i) is carried out at a range of from 60℃ to 90℃.

13. The continuous-flow synthetic method according to claim 1, wherein the step (ii) is carries out at a range of from 10℃ to room temperature.

14. The continuous-flow synthetic method according to claim 1, wherein the pharmaceutically acceptable salt of the compound is a sodium salt.

Citation Information

Patent Citations

  • Production of cefazolin

    JP1998101679A

  • Process for preparing cefazolin

    US3954745A

  • Simple enzymatic process for preparing cefazolin

    WO2004039997A1

  • IN193MUN2009A